Hisashi Hidaka Selected Research

Thrombocytopenia (Thrombopenia)

12/2023	Introduction of direct-acting antiviral agents alters frequencies of anti-GPIIb/IIIa antibody-producing B cells in chronic hepatitis C patients with thrombocytopenia.
11/2022	B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis.
5/2022	A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
4/2022	Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.
1/2021	Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
1/2019	Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
3/2014	Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report.
8/2009	Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation.
8/2002	Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hisashi Hidaka Research Topics

Disease

43	Hepatocellular Carcinoma (Hepatoma) 03/2024 - 03/2005
13	Liver Cirrhosis (Hepatic Cirrhosis) 04/2024 - 08/2002
13	Neoplasms (Cancer) 01/2022 - 03/2005
11	Fibrosis (Cirrhosis) 10/2023 - 08/2002
9	Thrombocytopenia (Thrombopenia) 12/2023 - 08/2002
8	Liver Diseases (Liver Disease) 12/2023 - 10/2017
6	Ascites 07/2021 - 03/2017
5	Chronic Hepatitis C 12/2023 - 09/2012
5	Thrombosis (Thrombus) 01/2023 - 05/2014
5	Hemorrhage 11/2020 - 12/2007
5	Infections 04/2019 - 08/2010
3	Hepatic Encephalopathy 01/2022 - 05/2019
3	Esophageal and Gastric Varices (Esophageal Varices) 11/2020 - 05/2016
3	Portal Hypertension 09/2020 - 12/2007
3	Body Weight (Weight, Body) 09/2020 - 03/2017
3	Neoplasm Metastasis (Metastasis) 03/2015 - 01/2012
2	End Stage Liver Disease 01/2023 - 01/2020
2	Disease Progression 05/2022 - 04/2011
2	Hypertension (High Blood Pressure) 05/2022 - 01/2018
2	Fatigue 05/2022 - 01/2017
2	Alcoholic Fatty Liver 07/2021 - 01/2021
2	Hepatitis B 01/2021 - 03/2011
2	Brain Diseases (Brain Disorder) 01/2020 - 04/2018
2	Drug-Related Side Effects and Adverse Reactions 01/2019 - 04/2011
1	Inflammation (Inflammations) 04/2024
1	Adenocarcinoma 12/2022
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 11/2022
1	Wandering Spleen 07/2022
1	Proteinuria 05/2022
1	Sudden Death 05/2022
1	Anorexia 05/2022
1	Necrosis 01/2022
1	Sarcopenia 09/2021
1	Myocarditis (Carditis) 08/2021
1	Fatty Liver 07/2021
1	Autoimmune Hepatitis 01/2021
1	Gastroesophageal Reflux (GERD) 11/2020
1	Heartburn (Pyrosis) 11/2020
1	Ulcer 11/2020
1	Varicose Veins (Varicose Vein) 01/2020
1	Rupture 01/2020
1	Diarrhea 01/2020
1	Liver Neoplasms (Liver Cancer) 01/2020
1	Vomiting 01/2020
1	Non-alcoholic Fatty Liver Disease 04/2019

Drug/Important Bio-Agent (IBA)

16	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 08/2010
12	lenvatinibIBA 12/2022 - 01/2020
6	BilirubinIBA 09/2021 - 08/2002
5	Bevacizumab (Avastin)FDA Link 03/2024 - 08/2021
5	atezolizumabIBA 03/2024 - 08/2021
4	Alanine Transaminase (SGPT)IBA 04/2024 - 08/2002
4	lusutrombopagIBA 04/2022 - 12/2018
4	AlbuminsIBA 09/2021 - 03/2005
3	Antiviral Agents (Antivirals)IBA 12/2023 - 01/2021
3	Carrier Proteins (Binding Protein)IBA 12/2023 - 11/2018
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 05/2022 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 08/2010
3	DiureticsIBA 01/2020 - 03/2017
3	InterferonsIBA 04/2018 - 09/2012
2	AutoantibodiesIBA 12/2023 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2023 - 08/2021
2	SodiumIBA 01/2023 - 03/2017
2	Thrombopoietin (c-mpl Ligand)IBA 01/2021 - 08/2002
2	Tolvaptan FDA Link 01/2020 - 03/2017
2	wisteria lectinIBA 05/2019 - 11/2018
2	Branched-Chain Amino AcidsIBA 12/2017 - 02/2013
2	Ribavirin (Virazole)FDA LinkGeneric 03/2014 - 09/2012
2	Prothrombin (Factor II)IBA 06/2013 - 08/2009
2	Serum AlbuminIBA 02/2013 - 03/2005
2	olmesartanIBA 11/2011 - 12/2007
2	Surface Antigens (Surface Antigen)IBA 03/2011 - 08/2010
1	EnzymesIBA 12/2023
1	UreaseIBA 10/2023
1	Glycoproteins (Glycoprotein)IBA 11/2022
1	B-Cell Activating FactorIBA 11/2022
1	Inosine Triphosphate (ITP)IBA 11/2022
1	Platelet Membrane Glycoprotein IIbIBA 11/2022
1	AntibodiesIBA 11/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2022
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 07/2022
1	Carnitine (L-Carnitine)FDA LinkGeneric 01/2022
1	Phospholipases (Phospholipase)IBA 01/2022
1	Rifaximin (L 105)FDA Link 01/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	AntacidsIBA 11/2020
1	AcidsIBA 11/2020
1	Nitric Oxide Synthase (NO Synthase)IBA 10/2020
1	Tyrosine Kinase InhibitorsIBA 09/2020
1	Furosemide (Lasix)FDA LinkGeneric 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 04/2019

Therapy/Procedure

25	Therapeutics 01/2023 - 03/2005
6	Radiofrequency Ablation 04/2019 - 03/2005
4	Drug Therapy (Chemotherapy) 05/2022 - 08/2010
3	Ligation 11/2020 - 12/2007
3	Radiotherapy 05/2014 - 01/2007
1	Thrombolytic Therapy 01/2023
1	Splenectomy 07/2022
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 07/2022
1	Molecular Targeted Therapy 01/2022
1	Drug Tapering 01/2020